To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Top Cited Papers
- 5 November 2018
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 78 (2), 192-200
- https://doi.org/10.1136/annrheumdis-2018-213474
Abstract
Objectives Real-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) in 2016. Clinical characteristics and treatment outcomes were studied in ETA-treated patients, who switched to SB4 (switchers) or maintained ETA (non-switchers). Retention rates were compared with that of a historic cohort of ETA-treated patients. Switchers who resumed ETA treatment (back-switchers) were characterised. Methods Observational cohort study based on the DANBIO registry. Treatment retention was explored by Kaplan-Meier plots and Cox regression (crude, adjusted). Results 1621 (79%) of 2061 ETA-treated patients switched to SB4. Disease activity was unchanged 3 months’ preswitch/postswitch. Non-switchers often received 25 mg ETA (ETA 25 mg pens/syringes and powder solution were still available). One-year adjusted retention rates were: non-switchers: 77% (95% CI: 72% to 82%)/switchers: 83% (79% to 87%)/historic cohort: 90% (88% to 92%). Patients not in remission had lower retention rates than patients in remission, both in switchers (crude HR 1.7 (1.3 to 2.2)) and non-switchers (2.4 (1.7 to 3.6)). During follow-up, 120 patients (7% of switchers) back-switched to ETA. Back-switchers’ clinical characteristics were similar to switchers, and reasons for SB4 withdrawal were mainly subjective. Conclusion Seventy-nine per cent of patients switched from ETA to SB4. After 1 year, adjusted treatment retention rates were lower in switchers versus the historic ETA cohort, but higher than in non-switchers. Withdrawal was more common in patients not in remission. The results suggest that switch outcomes in routine care are affected by patient-related factors and non-specific drug effects.Keywords
Funding Information
- Biogen
This publication has 34 references indexed in Scilit:
- Patient attitudes and understanding about biosimilars: an international cross-sectional surveyPatient Preference and Adherence, 2016
- The nocebo effect of drugsPharmacology Research & Perspectives, 2016
- The changing landscape of biosimilars in rheumatologyAnnals Of The Rheumatic Diseases, 2016
- Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical TrialsArthritis Care & Research, 2016
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opinion on Biological Therapy, 2015
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapyAnnals Of The Rheumatic Diseases, 2015
- Medicine's inconvenient truth: the placebo and nocebo effectInternal Medicine Journal, 2014
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- European biologicals registers: methodology, selected results and perspectivesAnnals Of The Rheumatic Diseases, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987